Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
363 Results Found
Walmart, Transcarent Team Up to Woo Self-Insured Employers
Walmart recently partnered with the consumer-facing health care platform Transcarent to provide low-cost prescription drugs, telehealth, optical and other services to self-insured employers.
AHA reiterates support for most-favored nation drug price rule’s withdrawal
The AHA restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule.
AHA Comments on the Centers for Medicare & Medicaid Services’ Most Favored Nation Model Proposed Rule
This letter to CMS reiterates AHA’s position that the agency’s Most Favored Nation Proposed Rule should be withdrawn.
AHA, Others Urge Congressional Leaders to Protect 340B Program as They Consider Legislation Under Reconciliation
AHA, others express support of the 340B federal drug pricing program and strongly encourage Congress to protect the program as they consider broader changes to our nation’s health care system.
Fact Sheet: AHA Priorities for Budget Reconciliation Package to Support America’s Hospitals and Health Systems
It is imperative that Congress invest in America’s hospitals and health systems to ensure
that the nation’s health care needs can be met today and into the future. The AHA supports
investments in infrastructure, such as the health care workforce, behavioral health, the
accessibility and affordability of health care coverage, emergency preparedness and the health
care supply chain, telehealth and cybersecurity, among other areas.
HHS outlines plan to lower the nation’s prescription drug costs
A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The report recommends the pursuit of legislation that would enable price negotiation in Medicare Parts B and D, with those negotiated prices also available to the federal marketplace, commercial plans and employers who want to participate; Medicare Part D reform, including a cap on beneficiary out-of-pocket spending; and legislation that would slow price increases over time on existing drugs and speed entry of biosimilars and generics to the marketplace while increasing their prescribing by clinicians.
AHA Letter to House and Senate Sharing Priorities in Upcoming Budget Reconciliation Legislation
The American Hospital Association (AHA) would like to share hospital and health system priorities that would benefit patients and communities around the country that we would like to see included in the upcoming budget reconciliation legislation.
Senate holds hearing on anticompetitive drugmaker conduct
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.
House committee report shines light on pharma’s pricing, business practices
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released by the House Committee on Oversight and Reform.